M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity Pharmaceutical TechnologyThrough this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).NeuroscienceRead full story pharminent August 4, 2026 (Last updated: August 8, 2026) Pharmaceutical Technology Through this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs). Neuroscience Read full story Post navigation Previous: Pathos AI signs two cancer deals with Alphamab and AZNext: Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout Related Stories M&A / Deals China’s Haisco forms immunology biotech with up to $1.5B from American VCs pharminent August 25, 2026 M&A / Deals Roche commits to lean-mass preservation with Hanmi obesity deal pharminent August 24, 2026 M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026
